Manoussos Perros - Jul 16, 2021 Form 4 Insider Report for Entasis Therapeutics Holdings Inc. (ETTX)

Role
President and CEO
Signature
Elizabeth M. Keiley as Attorney-in-Fact for Manoussos Perros
Stock symbol
ETTX
Transactions as of
Jul 16, 2021
Transactions value $
$0
Form type
4
Date filed
2/15/2022, 03:04 PM
Next filing
Oct 20, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ETTX Employee Stock Option (Right to Buy) Disposed to Issuer -87.5K -100% 0 Jul 16, 2021 Common Stock 87.5K $4.98 Direct F1, F2
transaction ETTX Employee Stock Option (Right to Buy) Award +58.3K 58.3K Jul 16, 2021 Common Stock 58.3K $2.44 Direct F2, F3
transaction ETTX Employee Stock Option (Right to Buy) Disposed to Issuer -167K -100% 0 Jul 16, 2021 Common Stock 167K $6.85 Direct F4, F5
transaction ETTX Employee Stock Option (Right to Buy) Award +129K 129K Jul 16, 2021 Common Stock 129K $2.44 Direct F5, F6
transaction ETTX Employee Stock Option (Right to Buy) Disposed to Issuer -79.7K -100% 0 Jul 16, 2021 Common Stock 79.7K $15.00 Direct F7, F8
transaction ETTX Employee Stock Option (Right to Buy) Award +44.3K 44.3K Jul 16, 2021 Common Stock 44.3K $2.44 Direct F8, F9
transaction ETTX Employee Stock Option (Right to Buy) Disposed to Issuer -124K -100% 0 Jul 16, 2021 Common Stock 124K $5.66 Direct F10, F11
transaction ETTX Employee Stock Option (Right to Buy) Award +95K 95K Jul 16, 2021 Common Stock 95K $2.44 Direct F11, F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option will vest on May 13, 2016, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to Reporting Person continuing to provide service through each such date.
F2 On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 87,462 shares of issuer's common stock granted to the Reporting Person on August 11, 2015. In exchange, the Reporting Person received a replacement option for 58,307 shares of issuer's common stock, having an exercise price of $2.44 per share.
F3 The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date.
F4 The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option will vest on December 6, 2018, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the last day of the month, subject to Reporting Person continuing to provide service through each such date.
F5 On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 166,623 shares of issuer's common stock granted to the Reporting Person on May 1, 2018. In exchange, the Reporting Person received a replacement option for 128,531 shares of issuer's common stock, having an exercise price of $2.44 per share.
F6 The shares subject to this option will vest in full on July 16, 2022, subject to the Reporting Person's continuing to provide service through such date.
F7 The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option shall vest on September 25, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
F8 On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 79,698 shares of issuer's common stock granted to the Reporting Person on September 25, 2018. In exchange, the Reporting Person received a replacement option for 44,276 shares of issuer's common stock, having an exercise price of $2.44 per share.
F9 Ninety-four (94%) of this award will vest on July 16, 2022, and one-third of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.
F10 The option provided for vesting as follows: Twenty-five percent (25%) of the shares subject to the option shall vest on January 1, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
F11 On July 16, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 123,500 shares of issuer's common stock granted to the Reporting Person on January 18, 2019. In exchange, the Reporting Person received a replacement option for 95,000 shares of issuer's common stock, having an exercise price of $2.44 per share.
F12 Eighty-five (85%) of this award will vest on July 16, 2022, and one-seventh of the remaining shares subject to the option will vest monthly following July 16, 2022, subject to the Reporting Person's continuing to provide service through each such date.